irritable bowel syndrome with constipation (IBS-C)

Arena Pharmaceuticals
Biotech

Arena fails phase 2b, prompting review of 'strategic options'

The cannabinoid receptor 2 agonist failed to reduce abdominal pain, but Arena pointed to a subgroup analysis as evidence of efficacy.
Nick Paul Taylor Mar 3, 2021 7:40am
stop sign knerri61Pixabay

Synthetic Biologics cans phase 2 IBS trial deemed likely to fail

Oct 2, 2020 10:25am
Mike Raab - Ardelyx

Ardelyx rises on better IBS data and clearer path to FDA filing

Oct 12, 2017 8:08am
Research

Struggling Ardelyx cuts staff, places bets on its late-stage pipeline

Aug 9, 2017 9:26am